Epsilon M&A Deal Report - Biofutur
Transaction Multiples for the Valuation of Private Companies
Private Group led by Omnes Capital / Biofutur
No EMAT :
100831
Announced Date :
30/11/2019
Type :
LBO (Leverage Buy Out)
Deal Value :
Yes
Acquirer :
Private Group led by Omnes Capital
Target :
Biofutur
Country :
Val-D'Oise
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Medical Diagnostic Laboratory
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Biomedical Research Laboratory
Business Description :
Biofutur is a group of medical biology analysis laboratories in Ile-de-France. > P rovides diagnostic services in the areas of allergies, chemical pathology, haematology, hemostasis, immunoanalysis,...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
|
|||||
| Current |
Rating :
*
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Medical Diagnostic Laboratory » = 51
- Number of EMAT Reports / sub-sector « Biomedical Research Laboratory » = 34
| Date | Acquirer | Target | Country | Multiples | See details |
| 21/06/2019 | Karo Pharma | Trimb | Sweden | *** | 100797 |
| 14/10/2016 | Sodalco | Lycia Brand of Artsana | Italy | * | 100713 |
Source: Epsilon Research / EMAT
